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Abstract
Background: Atypical antipsychotics provide better control of the negative and affective symptoms of schizophrenia 
when compared with conventional neuroleptics; nevertheless, their heightened ability to improve cognitive 
dysfunction remains a matter of debate. This study aimed to examine the changes in cognition associated with long-
term antipsychotic treatment and to evaluate the effect of the type of antipsychotic (conventional versus novel 
antipsychotic drugs) on cognitive performance over time.
Methods: In this naturalistic study, we used a comprehensive neuropsychological battery of tests to assess a sample of 
schizophrenia patients taking either conventional (n = 13) or novel antipsychotics (n = 26) at baseline and at two years 
after.
Results: Continuous antipsychotic treatment regardless of class was associated with improvement on verbal fluency, 
executive functions, and visual and verbal memory. Patients taking atypical antipsychotics did not show greater 
cognitive enhancement over two years than patients taking conventional antipsychotics.
Conclusions: Although long-term antipsychotic treatment slightly improved cognitive function, the switch from 
conventional to atypical antipsychotic treatment should not be based exclusively on the presence of these cognitive 
deficits.
Background
Cognitive disturbances are a core feature of schizophre-
nia and have been extensively studied in recent years [1].
Cognitive impairment is present before the onset of the
illness [2] and is also found in healthy relatives of
patients, although to a lesser degree [3]. In addition, this
feature is not exclusively secondary to psychiatric symp-
toms or medication [4]. Cognitive impairment is a better
predictor of future functional outcomes compared with
positive symptoms [5-7].
The positive action of conventional antipsychotics
drugs (APDs) on cognition is considered mild or moder-
ate [8] and is limited to certain cognitive domains such as
sustained attention [9,10].
Regarding novel antipsychotics, this supposed cogni-
tive enhancement would be mediated by their capability
to raise the level of dopamine and acetylcholine in pre-
frontal regions [11]. However, their different affinity for
brain receptors may result in different procognitive pro-
files of each class of antipsychotics. Many studies support
a cognitive enhancement of the different atypical antipsy-
chotics: quetiapine and olanzapine [12], quetiapine and
risperidone [13], ziprasidone and olanzapine [14]; olan-
zapine, quetiapine, and risperidone [15], risperidone and
quetiapine focusing in schizophrenia with predominantly
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Page 2 of 10negative symptoms [16]. Moreover, this favorable effect
on cognition seems to persist after controlling for con-
founding variables such as clinical state, learning, and
cooperation [17]. Nevertheless, some authors [18] have
reported a worsening in a working memory task in first
episode schizophrenic patients after treatment with atyp-
ical antipsychotics.
Studies that attempted to demonstrate the association
of a greater cognitive enhancement with novel versus
conventional APDs are susceptible to biases and face sev-
eral difficulties, which include confounding effects of
clinical symptoms, previous and adjunctive medications
(i.e., anticholinergics and benzodiazepines), and practice
effects, especially when intervals between assessments
are short [19,20].
Many studies have compared the procognitive proper-
ties of conventional and atypical APDs. Results that
stemmed from these various reports were compiled by
Woodward et al. [21] in a meta-analysis of 14 typical/
atypical comparative studies; these authors concluded
that atypical APDs improve overall cognitive function to
a higher degree than typical APDs.
Despite all these data, the benefits of atypical APDs
over conventional APDs for the full range of cognitive
disturbances in schizophrenia remain controversial, espe-
cially for the most severe impairments, i.e., serial learn-
ing, executive functioning, vigilance, motor speed, and
verbal fluency [22]. Several authors suggest that the dif-
ference in potency between these two APD types, if any,
is small [19]. Recently, results of the neurocognitive com-
ponent of the Clinical Antipsychotic Trials of Interven-
tion Effectiveness (CATIE), which is a NIMH-sponsored
study, did not indicate a better procognitive profile of
four atypical APDs when compared with the conven-
tional APD perphenazine [23].
Most of the studies comparing typical versus atypical
antipsychotics on cognitive performance are randomized
blind trials. Since many clinicians consider changing from
conventional to novel antipsychotics in order to enhance
cognition, we think that naturalistic studies may provide
a closer look to real clinical practice.
In the present naturalistic, retrospective study, we used
a comprehensive neuropsychological battery of tests to
assess the cognitive outcome in two groups of schizo-
phrenic patients: the first group was treated with one or
more conventional APDs over two years, while the sec-
ond group was treated with one atypical APD. The treat-
ments were not discontinued at any time and there were
no switches in the type of APD administered. Patients'
performance on tasks of executive functions, verbal
working memory, short-term memory, verbal memory,
visual memory, speed of processing, verbal fluency, and
motor speed were assessed twice, two years apart.
The first objective of this study was to examine changes
in cognitive impairment associated with long-term APD
treatment. The second objective was to assess the effect
of the type of antipsychotic treatment on change of cog-
nition over two years and describe the potential differ-
ences between the groups.
Methods
Subjects
Subjects who participated in this observational and natu-
ralistic study were enrolled in the Valencia Follow-Up
Study of Schizophrenia and Bipolar I Disorder [24-26].
Fifty-two patients who fulfilled the DSM-IV criteria for
schizophrenia [27] were recruited over nine months
among individuals attending three psychiatric outpatient
units in Valencia, Spain. Diagnoses were confirmed by
the Schedules for Clinical Assessment in Neuropsychia-
try (SCAN) and the CATEGO computer program [28]
after a minimum disease progress of two years. The
cohort of patients was divided into two groups according
to the type of antipsychotic treatment. Only patients who
took the same type of medication (conventional or atypi-
cal APDs) and were not hospitalized for the entire two
years were evaluated. Changes in dosage were permitted.
Thirty-nine patients from the original cohort of schizo-
phrenic individuals met these criteria. One group (n = 13,
9 men, 4 women) was composed of patients being treated
with conventional antipsychotics (fluphenazine, n = 7;
haloperidol, n = 2; perphenazine, n = 1; and haloperidol
plus fluphenazine, n = 3) and the second group (n = 26,
18 men, 8 women) comprised patients who were taking
an atypical antipsychotic (olanzapine, n = 13; risperidone,
n = 7; and quetiapine, n = 6).
All participants were assessed at baseline (T1) and two
years later (T2). Most patients in this study were treated
in settings that did not offer psychosocial rehabilitation
programs. At each time point, all patients were medi-
cated by their psychiatrists in a naturalistic manner. The
average daily dose of APD was converted into chlorprom-
azine equivalent (CPZ) units, for statistical purposes
[29,30]. The doses of benzodiazepines were converted to
diazepam equivalent units. Biperiden was the only anti-
cholinergic drug administered to the patients.
Written informed consent was obtained from all partic-
ipants after an explanation of the study procedures. The
Ethics Committee of the University Clinic Hospital of
Valencia approved the research protocol.
Clinical assessment
The clinical evaluation of each patient was rated accord-
ing to the Positive and Negative Symptom Scale (PANSS)
[31,32] and to the Hamilton Rating Scale for Depression
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Page 3 of 10(HRSD) [33,34]. Premorbid adjustment was assessed
using the Phillips Adjustment Scale [35].
Neuropsychological evaluation
All patients completed a battery of tests, which were
described in three previous publications [36,7,37]. These
tests were used to measure eight neurocognitive
domains, in the following sequence. This sequence was
always the same for all patients and took 90 minutes
approximately in one experimental session.
1) Executive Functions/Reasoning and Problem Solving
(Wisconsin Card Sorting Test [WCST] measuring Cate-
gories, Total errors and Perseverative Errors; Trail Mak-
ing Test part B; and Color-Word Interference Trial of the
Stroop Color and Word Test).
2) Short-term Memory (Digit Span Forward Test)
3) Working Memory (backward part of the Digit Span
Test from the Wechsler Adult Intelligence Scale-Revised
[WAIS-R]).
4) Verbal Memory (Babcock Story Recall Test)
5) Visual Memory (Rey-Osterrieth Complex Figure
Test). Immediate and differed (30 minutes) recall.
6) Visual-Motor Processing/Speed of Processing (Trail
Making Test part A; Digit Symbol Substitution Test
[DSST] from the WAIS-R).
7) Semantic Verbal Fluency (FAS Test from the Con-
trolled Oral Word Association Test and the Category
Instant Generation Test [CIG]).
8) Motor Speed (Finger-Tapping Test in unimanual and
bimanual conditions).
The variable years of education was used as a measure
of premorbid intelligence.
Data analyses
Data analyses were carried out using the SPSS software
(version 15.0 for Windows). An alpha level of 0.05 was
used for all statistical tests. Data were analyzed using Stu-
dent's paired t test to compare the means (T1 vs. T2) for
all patients, as well as for each treatment group at T1. In
each group, changes in cognitive and clinical scores were
analyzed using an analysis of variance (ANOVA) with
repeated measures. Cognitive performance at T1 and T2
were the dependent variables and the type of APD was
the independent variable. As CPZ units and PANSS posi-
tive scores at T1 were the only variables differing between
that reached statistical significance, they were entered as
covariates in these analyses.
Pearson correlations were calculated among the clini-
cal, treatment, and outcome variables at T1 and for the
difference in neurocognitive scores (T2-T1) for every
cognitive variable. This new variable was calculated to
better assess the evolution of cognitive performance. Two
sets of correlation analyses were carried out by splitting
the cohort of patients according to the type of antipsy-
chotic medication taken.
Linear regression analyses with a forward stepwise pro-
cedure were performed to assess the relative contribu-
tions of the variables cited above. In this model, the type
of antipsychotic medication and the clinical, outcome,
and treatment variables at baseline that significantly cor-
related with neurocognitive measures (P ≤ 0.05) in any of
the two correlations were entered in the regression mod-
els as independent variables. The dependent variable was
the T2-T1 difference in performance on each neuropsy-
chological test.
Results
General characteristics of patients
The total sample comprised 27 men and 12 women. The
mean age of all patients was 32.9 (SD [standard deviation]
= 8.30) years, the mean length of education was 10.1 (SD
= 3.01) years, the mean age at onset was 24.94 (SD = 7.05)
years, and the mean number of prior episodes was 2.25
(SD = 1.59). The mean dose of APDs was 773.97 (SD =
514.63) CPZ units and the mean dose of anticholinergic
medication (biperiden) was 0.53 mg (SD = 1.33). The
mean dose of benzodiazepines was 3.55 (SD = 8.94) diaz-
epam equivalent units. At baseline, nine (5 from the typi-
cal APD group and 4 from the atypical APD group) out of
the 39 patients were taking benzodiazepines. At endpoint
eight were taking benzodiazepines (3 from the typical
APD group and 5 from the atypical APD group). Eight
patients were on biperiden at baseline (4 from each
group) and four at endpoint (2 each).
Patients' cognitive performance on the different tests
ranged around 2-3 standard deviations under normative
data for age and education-matched healthy Spanish pop-
ulation, with exception of the digit span test. [Mean
whole sample of patients for TMA test = 65.20 vs. 24.40
(SD = 8.71) for normal population; Mean TMB test =
162.71 vs. 50.68 (SD = 12.36); Rey Figure = 13.44 vs. 21.48
(SD = 5.54); FAS (verbal fluency) = 25.05 vs. 38.75 (SD =
4.80); Mean for Stroop test (word/color interference) =
82.0 vs. 49 (SD = 15.5). See Ardila et al [38] for complete
mean scores in Spanish population.
The baseline between-group comparison is summa-
rized in Table 1. Differences were observed in two vari-
ables: the PANSS positive subscale score and CPZ units
(both were used as covariables in repeated measures
analyses). Regarding the cognitive variables at baseline,
the group treated with conventional APDs showed a
poorer performance in the Trail Making Test part B (t =
2.69; P = 0.01) and committed more total errors in the
WCST (t = 2.14; P = 0.03). Sex distribution was equal in
both groups.
Clinical and neurocognitive changes in all patients
Significant differences between T1 and T2 were observed
for the following cognitive measures.
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pharmacological, and clinical variables.
Conventional APD Atypical APD t P
Mean SD Mean SD
Age 33.69 10.03 32.69 7.49 0.350 0.728
Years of education 9.15 3.33 10.73 2.76 -1.56 0.126
Age at onset 22.76 5.44 26.03 7.60 -1.37 0.176
Years of illness 10.92 8.83 6.65 5.98 1.78 0.082
Number of prior episodes 2.91 1.97 1.91 1.28 1.83 0.075
Chlorpromazine 
equivalent units
1116.15 708.97 602.88 264.60 3.29 0.002
Biperiden (mg) 1.08 1.98 0.30 0.78 1.75 0.087
Diazepam units 6.43 10.48 2.11 7.89 1.44 0.158
Number of APD 1.23 1.59 1.00 0.00 1.99 0.054
PANSS positive 17.84 4.89 10.15 2.98 6.093 0.0001
PANSS negative 19.69 9.12 21.11 8.82 -0.470 0.641
PANSS general 31.61 8.69 30.11 7.07 0.578 0.567
PANSS total 69.15 17.36 61.38 16.32 1.37 0.178
HRSD-21 4.87 3.56 6.12 4.97 -0.65 0.519
Premorbid adjustment 4.50 1.06 3.60 2.14 0.113 0.265
APD: Antipsychotic Drug; SD: Standard Deviation; HRSD-21: Hamilton Rating Scale for Depression, 21 items
A) Semantic verbal fluency, as assessed using the CIG
test (t = -4.14; P < 0.000; d =.664) and FAS Test (t = -3.76;
P = 0.001; d =.602).
B) Executive functions, as assessed using the WCST for
total errors (t = 2.03, P = 0.04; d =.324) and for persevera-
tive errors (t = 2.15; P = 0.03; d = 344), the Color/Word
interference part of the Stroop Test (t = 2.77; P = 0.009; d
= 0.444), and the Trail Making Test part B (t = 2.74; P =
0.009; d = 0.440).
C) Auditory verbal memory, as assessed using the Digit
Span Forward Test (t = 3.89; P < 0.000; d = .620).
D) Visual memory, as assessed using the Rey-Osterrieth
Complex Figure Test for immediate (t = -4.26; P < 0.000; d
=.681) and delayed (t = -3.35; P = 0.002; d =.536) visual
recall.
Considering the whole sample, no differences were
observed between T1 and T2 for the various PANSS sub-
scales.
The repeated measures analyses did not reveal any
main effect of the patient group (conventional or atypical
APDs) on any of the cognitive tests used (Table 2); how-
ever, major effects of the patient group were observed for
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(Table 3).
Correlational analyses
Significant correlations between outcome, clinical, and
treatment variables at T1 and T2-T1 and neuropsycho-
logical change scores for the two patient groups are
shown in supplemental material. Age, age at onset, length
of illness, and number of prior episodes and hospitaliza-
tions did not correlate with any of the neurocognitive
variables.
Regression analyses (see table 4)
The type of antipsychotic medication did not predict
the performance in any neuropsychological test. Dosage
of biperiden significantly predicted the performance in
the Stroop Test (R2 = 0.132; P = 0.02); WCST errors (R2 =
0.226; P = 0.01); and Finger Tapping Test, right motor
performance (R2 = 0.179; P = 0.007). Diazepam equivalent
units significantly predicted the number of total errors in
the WCST test (R2 = 0.116; P = 0.03).
Concerning clinical variables, the PANSS General Psy-
chopathology subscale significantly predicted the perfor-
mance in the Category Instant Generation Test (R2 =
0.167; P = 0.01).
Discussion
The results from this pilot, naturalistic study suggest sig-
nificant, but heterogeneous cognitive improvements for
the total sample of schizophrenic subjects after two years
of continuous antipsychotic treatment. Improvement was
observed in the domains of semantic verbal fluency, exec-
utive functions, visual memory, and auditory immediate
memory. Size effects of the differences were moderate
with a more clinical relevance in the two verbal fluency
tasks and visual/auditory memory (Rey figure immediate
recall and Digit Span Test forward), where size effects
were all over 0.6. In the opposite, after two years of treat-
ment no cognitive improvements were observed in
visual/motor processing, motor speed and working mem-
ory tasks.
As patients did not participate in psychotherapeutic
interventions or programs aimed at improving cognitive
function and considering the absence of significant differ-
ences between T1 and T2 in the PANSS scores, we sug-
gest that these cognitive gains may be in part the result of
continuous exposure to antipsychotic medication. More-
over, the characteristics of the sample in the present study
correspond to clinically stable, chronic patients, previ-
ously stabilized by the ongoing antipsychotic medication,
so the effects psychopathological changes on cognition,
although not measured, are probably limited.
The relatively long time interval between the baseline
and the endpoint would rule out, at least in part, learning
effects associated with repeated testing [39,20].
The cognitive improvement observed in our cohort
supports the results obtained in the neurocognitive com-
ponent of the CATIE trial [15] and in a recent naturalistic
study [40], which reported an improvement in cognition
after six months of continuous treatment with APDs. The
positive change described in the present study seems to
exclude a potential deleterious effect of conventional
APDs on a wide range of neuropsychological parameters
even at the moderate-to-high dosages used here (CPZ
units = 1116). As the procognitive advantages of atypical
APDs reported in comparative studies, which could be
caused by the use of high dosages of the drugs adminis-
tered in the conventional APD group [8], remain contro-
versial, the absence of differences in the present study can
be considered more robust. Nevertheless, high dosages of
conventional antipsychotics may probably impair cogni-
tion as dose reduction in patients with high dosages may
lead to cognitive improvement, as shown recently [41].
Our results do not support the hypothesis of a better
cognitive outcome in patients treated with atypical APD.
The variable "type of APD" did not predict the improve-
ment of performance in any of the neuropsychological
tests, as assessed using regression analyses; however,
intake of anticholinergic drugs seems to predict cognitive
changes significantly. These results support other studies
that concluded that concurrent use of anticholinergic
drugs, especially their acute administration [42], is
another possible explanation for the negative effects of
these drugs on cognition reported in the literature
[39,43]. In addition, this provides a further reason to
avoid these drugs and the antipsychotics that require this
sort of adjunctive medication to prevent extrapyramidal
symptoms.
In contrast to the similar effect on cognitive evolution
observed for both types of APDs, a significant improve-
ment in the PANSS positive subscale score was detected
in the group treated with conventional APDs. Interest-
ingly, another significant effect, which translated into an
improvement in the PANSS General Subscale score, was
observed in the group treated with atypical APDs, which
suggests a positive effect of these new drugs on the
nonpsychotic symptoms of schizophrenia.
The limitations of the present study should be taken
into account. Firstly, the relatively small sample size and
the consequent lack of statistical power may have masked
possible differences between the groups. In addition,
these factors did not allow us to perform head-to-head
comparisons of specific APDs. Secondly, as this was not a
blind trial and patients were not randomly assigned to
Selva-Vera et al. BMC Psychiatry 2010, 10:47
http://www.biomedcentral.com/1471-244X/10/47
Page 6 of 10
Table 2: Effect of the type of antipsychotic treatment on the evolution of cognitive performance (repeated measures 
analysis)
Conventional APD Atypical APD F P
T1 T2 T1 T2
Mean SD Mean SD Mean SD Mean SD
Digit Span forward 5.58 1.11 5.16 0.98 5.92 1.29 5.30 1.22 0.014 0.906
Digit Span Backwards 3.42 0.95 3.58 0.75 3.92 1.67 3.76 1.24 0.601 0.443
WCST categories 3.15 1.72 3.75 1.92 4.15 2.46 4.46 2.12 0.155 0.697
WCST total errors 62.61 18.82 49.83 22.90 41.23 33.28 35.53 30.20 0.024 0.879
WCST perseverative errors 35.00 14.14 25.75 14.39 22.65 23.20 17.07 16.11 0.095 0.760
FAS Test 39.07 9.84 44.69 9.04 40.11 12.66 48.80 14.68 2.586 0.117
CIG Test 22.07 6.60 29.69 10.75 26.53 16.54 31.84 17.68 0.296 0.590
Trail Making part A 48.50 23.24 47.36 24.51 65.53 56.77 63.10 55.47 0.176 0.677
Trail Making part B 207.00 88.39 148.46 64.67 140.57 63.77 127.46 67.00 0.912 0.346
Digit Symbol 40.30 15.16 43.00 18.18 46.42 16.14 47.92 15.88 0.000 0.988
Stroop Color-Word trial (Interference) 86.53 28.13 66.43 17.35 79.73 42.13 71.11 35.21 0.054 0.818
Babcock Story Recall Test, Immediate 
memory
5.43 2.25 7.43 2.62 7.90 3.42 8.30 3.83 0.602 0.444
Babcock Story Recall Test, Delayed Recall 8.71 3.45 9.78 3.32 9.63 4.81 10.05 5.17 0.037 0.849
Rey Figure, Immediate 11.38 7.10 16.80 3.76 14.48 7.76 17.21 7.71 2.354 0.120
Rey Figure, 20 min 12.46 6.14 16.36 4.08 14.42 7.97 16.92 7.87 2.533 0.120
Finger-Tapping Test, Unimanual Left 
Motor Performance
53.69 10.57 57.38 16.28 58.15 21.09 66.80 12.66 1.489 0.231
Finger-Tapping Test, Unimanual Right 
Motor Performance
61.15 15.15 62.46 24.03 73.61 20.98 77.63 23.38 0.730 0.399
Finger-Tapping Test, Bimanual Left 
Motor Performance
52.92 12.02 54.07 16.13 60.80 19.93 66.75 19.21 0.113 0.739
Finger-Tapping Test, Bimanual Right 
Motor Performance
58.92 12.12 54.07 16.13 65.15 21.00 65.52 19.02 1.174 0.286
APD: Antipsychotic drug; DS: Standard Deviation; WCST: Wisconsin Card Sorting Test; CIG Test: Category Instant Generation Test.
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groups may simply reflect a prescription bias. According
to a recent meta-analysis [39], the differences in cognitive
outcomes observed between conventional and atypical
APDs in naturalistic, open-label studies are usually not
found in double-blind randomized trials. Nevertheless,
naturalistic studies have the advantage of using doses of
APDs that are closer to those applied in daily practice,
when compared with randomized clinical trials. The seg-
regation of different conventional and atypical APDs into
two groups represents the third limitation of this study.
Although this procedure may make sense based on the
clearly different mechanisms of conventional versus atyp-
ical APDs, it is also true that some intragroup differences
may exist, especially among subjects taking different
atypical APDs [44,12]. Finally, the cognitive improve-
ments observed for the schizophrenic patients after two
years of treatment could be questioned, as the present
study lacks a control group of healthy subjects. These
limitations are in part compensated by the two-year lapse
between the evaluations, which is substantially longer
than that of most published longitudinal studies compar-
ing conventional and atypical APDs. This long period of
continuous treatment may help to minimize learning
effects, which renders eventual differences between the
groups more robust. Several animal/preclinical studies
have demonstrated that both conventional and atypical
APDs increase neurogenesis and proliferation of nonneu-
ronal cells in the adult brain, particularly in some areas of
the hippocampus (see 45 for a review). This may result in
cognitive improvement in terms of memory and learning.
The translational effect of neurogenesis on cognitive
gains/enhancements can only be correctly evaluated by
longitudinal studies that incorporate more than a few
weeks between assessments.
Conclusions
Data from the literature showing that cognitive measures
can predict functional outcomes [6] emphasize the
importance of cognitive enhancement. Antipsychotic
continuous treatment represents one of the few ways to
remediate these deficits, albeit modestly. Therefore, strat-
egies aimed at improving treatment adherence may help
prevent cognitive decline and allostatic load [46].
Bearing in mind that this pilot study lacks a representa-
tive sample of patients, these preliminary finding are con-
sistent with the recent literature in which atypical
antipsychotics have not demonstrated cognitive benefits
over typical or conventional antipsychotics. Our results
did not show a clear advantage of atypical over conven-
tional APDs on cognitive performance, however, the gen-
eral improved tolerability profile of second generation
antipsychotics regarding neurological side effects may
facilitate treatment adherence, which in turn may result
in cognitive improvement. Anyway, in the absence of
other reasons to change ongoing treatment, which
include negative or affective symptoms or lack of compli-
ance with the regimen, the switch from typical APD at
Table 3: Effect of the type of antipsychotic treatment on the evolution of clinical measures (repeated measures analysis)
Conventional APD Atypical APD F P
T1 T2 T1 T2
Mean SD Mean SD Mean SD Mean SD
PANSS 
positive
17.84 4.89 13.46 4.46 10.15 2.98 11.73 4.63 7.719 0.009
PANSS 
negative
19.69 9.12 19.23 7.60 21.11 8.82 20.19 8.62 1.067 0.309
PANSS 
general
31.61 8.69 32.30 8.69 30.11 7.07 28.73 8.70 9.672 0.004
PANSS total 69.15 1.11 65.00 18.40 61.38 17.76 60.65 18.73 3.234 0.081
HRSD-21 4.87 3.56 5.62 1.92 6.12 4.97 6.80 5.30 0.835 0.369
APD: Antipsychotic drug; SD: Standard Deviation; PANSS: Positive and Negative Symptoms Scale; HRSD-21: Hamilton Rating Scale for 
Depression, 21 items
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based solely on the expectation of a more favorable cog-
nitive outcome. Nevertheless, other psychopharmacolog-
ical and psychosocial strategies should be implemented
to enhance cognitive outcome in schizophrenic patients.
Competing interests
Role of funding source
Funding for this study was provided by CIBERSAM, which had no further role in
study design, the collection, analysis, and interpretation of data, the writing of
the report, or in the decision to submit the paper for publication.
Dr. Vieta has received grants from or acted as a consultant for the following
companies: AstraZeneca, Bristol Myers-Squibb, Forest Research Institute, Glaxo
SmithKline, Janssen, Jazz Pharmaceuticals, Eli-Lilly, Lundbeck, MSD, Novartis,
Organon, Otsuka, Pfizer, Sanofi-Aventis, Servier, Schering-Plough, Solvay,
Takeda, United Biosource Corporation, and Wyeth.
Dr. Tabarés-Seisdedos has received grants from or acted as a consultant for the
following companies: AstraZeneca, Janssen, Eli-Lilly, Lundbeck, Novartis, Pfizer,
Sanofi-Aventis, and Wyeth that were deposited into research accounts at the
University of Valencia.
Dr. Balanzá-Martínez has received grants from or acted as a consultant for the
following companies: AstraZeneca, Boehringer Ingelheim, Bristol-Myers-
Squibb/Otsuka, Janssen-Cilag, Pfizer, and Wyeth.
Authors' contributions
All listed authors have contributed significantly to the manuscript and consent
to their names on the manuscript. GSV, RTS, VBM and JSF conceived of the
study, participated in its design and coordination and helped to draft the man-
uscript. PC collected data and carried out the neuropsychological assessments.
JSM, AMA and EV revised the article critically for important intellectual content.
All authors read and approved the final manuscript
Acknowledgements
This article was supported in part by grants from the following: Spanish Minis-
try of Science and Innovation, Institute of Health Carlos III (PI08/90416), CIBER-
SAM and Alicia Koplowitz Foundation to Dr. Tabarés-Seisdedos.
Author Details
1the Teaching Unit of Psychiatry and Psychological Medicine, Department of 
Medicine, University of Valencia, Blasco-Ibáñez 17, 46010 Valencia, Spain, 
2Ciber en Salud Mental (CIBERSAM). Instituto de Salud Carlos III, Madrid, Spain 
and 3the Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital 
Clinic of Barcelona, IDIBAPS, University of Barcelona, Villarroel 170, 08036 
Barcelona, Spain
References
1. Daban C, Martinez-Aran A, Torrent C, Tabarés-Seisdedos R, Balanza-
Martínez V, Salazar-Fraile J, Selva-Vera G, Vieta E: Specificity of cognitive 
deficits in bipolar disorder versus schizophrenia. A systematic review.  
Psychother Psychosom 2006, 75:72-84.
2. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, 
Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA: Predictors of 
treatment response from a first episode of schizophrenia or 
schizoaffective disorder.  Am J Psychiatry 1999, 156:544-549.
3. Hill SK, Harris MS, Herbner ES, Pavuluri M, Sweeney JA: Cognitive allied 
phenotypes for schizophrenia and bipolar disorder.  Schizophr Bull 
2008, 34:743-759.
4. Daban C, Amado I, Bourdel MC, Loo H, Olié JP, Poirier MF, Krebs MO: 
Cognitive dysfunctions in medicated and unmedicated patients with 
recent-onset schizophrenia.  J Psychiatr Res 2005, 39:391-398.
5. Breier A, Schreiber JL, Dyer J, Pickar D: National Institute of Mental Health 
longitudinal study of chronic schizophrenia. Prognosis and predictors 
of outcome.  Arch Gen Psychiatry 1991, 48:239-246.
6. Green M, Kern R, Heaton R: Longitudinal studies of cognition and 
functional outcome in schizophrenia: implications for MATRICS.  
Schizophr Res 2004, 72:41-51.
7. Tabarés-Seisdedos R, Balanzá-Martínez V, Sánchez-Moreno J, Martínez-
Arán A, Salazar-Fraile J, Selva-Vera G, Rubio C, Mata I, Gómez-Beneyto M, 
Vieta E, et al.: Neurocognitive and clinical predictors of functional 
outcome in patients with schizophrenia and bipolar I disorder at one-
year follow-up.  J Affective Dis 2008, 109:286-299.
Received: 20 December 2009 Accepted: 15 June 2010 
Published: 15 June 2010
This article is available from: http://www.biomedcentral.com/1471-244X/10/47© 2010 Selva-Vera et al; licensee BioMed Central Ltd. is an Open Access article distr but  under th  terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Psy hiatry 2010, 10:47
Table 4: Regression analysis
Dependent variable Variables included in the 
regression model
R2 F P
CIG (T2-T1) PANSS general 0.144 7.417 0.010
TMA Test (T2-T1) Biperiden 0.089 4.711 0.036
Stroop interference (T2-T1) PANSS negative 0.089 4.241 0.048
WCST total errors (T2-T1) Diazepam 0.092 4.871 0.034
Biperiden 0.183 5.253 0.010
Digit Symbol (T2-T1) Biperiden 0.130 6.666 0.014
Digit Span Backwards (T2-T1) EMC 0.092 4.830 0.034
Finger-Tapping Test, Unimanual 
Right Motor Performance (T2-T1)
Biperiden 0.157 8.057 0.007
CIG Test: Category Instant Generation Test; TMA Test: Trail Making Test, part A; WCST: Wisconsin Card Sorting Test; EMC: equivalents 
milligrams chlorpromazine.
Selva-Vera et al. BMC Psychiatry 2010, 10:47
http://www.biomedcentral.com/1471-244X/10/47
Page 9 of 108. Mishara AL, Goldberg TE: A meta-analysis and critical review of the 
effects of conventional neuroleptic treatment on cognition in 
schizophrenia: opening a closed book.  Biol Psychiatry 2004, 
55:1013-1022.
9. Mazur D, Hayes K: Relation of neuroleptic dose and tardive dyskinesia to 
attention, information-processing, and psychophysiology in 
medicated schizophrenics.  Arch Gen Psychiatry 1985, 34:633-644.
10. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG: Neuroleptics: effects on 
neuropsychological function in chronic schizophrenic patients.  
Schizophr Bull 1990, 16:477-499.
11. Stip E, Chouinard S, Boulay LJ: On the trail of a cognitive enhancer for 
the treatment of schizophrenia.  Prog Neuropsychopharmacol Biol 
Psychiatry 2005, 29:219-232.
12. Riedel M, Muller N, Spellmann I, Engel RR, Musil R, Valdevit R, Dehning S, 
Douhet A, Cerovecki A, Strassnig M, Möller HJ: Efficacy of olanzapine 
versus quetiapine on cognitive dysfunctions in patients with an acute 
episode of schizophrenia.  Eur Arch Psychiatry Clin Neurosci 2007, 
257:402-412.
13. Harvey PD, Patterson L, Zongh K, Brechner M: Improvement in social 
competence with short-term atypical antipsychotic treatment: a 
randomized, double-blind comparison of quetiapine versus 
risperidone for social competence, social cognition, and 
neuropsychological functioning.  Am J Psychiatry 2006, 163:1918-1925.
14. Harvey PD, Siu CO: Randomized, controlled, double-blind, multicenter 
comparison of the cognitive effects of ziprasidone versus olanzapine 
in acutely ill inpatients with schizophrenia or schizoaffective disorder.  
Psychopharmacology (Berl) 2004, 172:324-332.
15. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, 
Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, 
Perkins DO, Davis CE, Hsiao JK, Lieberman JA, CATIE Investigators; 
Neurocognitive Working Group: Neurocognitive effects of antipsychotic 
medications in patients with chronic schizophrenia in the CATIE Trial.  
Arch Gen Psychiatry 2007, 64:633-647.
16. Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit 
R, Engel RR, Kleindienst N, Müller N, Möller HJ: Effects of risperidone and 
quetiapine on cognition in patients with schizophrenia and 
predominantly negative symptoms.  Eur Arch Psychiatry Clin Neurosci 
2007, 257:360-370.
17. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger 
DR: Comparison of cognitive performances during a placebo period 
and an atypical antipsychotic treatment period in schizophrenia: 
critical examination of confounds.  Neuropsychopharmacology 2003, 
28:1491-1500.
18. Reilly JL, Harris MS, Khine TT, Keshavan MS, Sweeney JA: Antipsychotic 
drug exacerbate impairment on a working memory task in first-
episode schizophrenia.  Biol Psychiatry 2007, 62:818-821.
19. Harvey PD, Keefe RS: Studies of cognitive change in patients with 
schizophrenia following novel antipsychotic treatment.  Am J Psychiatry 
2001, 158:176-184.
20. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, 
Woerner MG, Schooler NR, Kane JM, Robinson DG: Cognitive 
improvement after treatment with second-generation antipsychotic 
medications in first-episode schizophrenia: is it a practice effect?  Arch 
Gen Psychiatry 2007, 64:1115-1122.
21. Woodward ND, Purdon SE, Meltzer H, Zaldh DH: A meta-analysis of 
neuropsychological change to clozapine, olanzapine, quetiapine, and 
risperidone in schizophrenia. Int J Neuropsychopharmacol.  2005, 
8:457-472.
22. Harvey PD, Rabinowitz J, Davidson M: Treatment of cognitive 
impairment in early psychosis: a comparison of risperidone and 
haloperidol in a large long-term trial.  Am J Psychiatry 2005, 
95:1888-1895.
23. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, 
Liebermann JA: Effects of olanzapine, quetiapine, and risperidone on 
neurocognitive function in early psychosis: a randomized, double-
blind 52-week comparison.  Am J Psychiatry 2007, 164:1061-1071.
24. Tabarés-Seisdedos R, Balanzá-Martínez V, Pallardó Y, Salazar-Fraile J, Selva 
G, Vilela C, Vallet M, Leal C, Gómez-Beneyto M: Similar effect of family 
history of psychosis on Sylvian fissure size and auditory P200 
amplitude in schizophrenic and bipolar subjects.  Psychiatry Res 2001, 
108:29-38.
25. Tabarés-Seisdedos R, Salazar-Fraile J, Selva-Vera G, Balanza-Martínez V, 
Ballester-Sánchez F, Cózar-Santiago R, Leal-Cercós C, Gómez-Beneyto M: 
Abnormal motor asymmetry only during bimanual movement in 
schizophrenic patients compared with healthy subjects.  Schizophr Res 
2003, 61:245-253.
26. Balanzá-Martínez V, Tabarés-Seisdedos R, Selva-Vera G, Martínez-Arán A, 
Torrent C, Salazar-Fraile J, Leal-Cercós C, Vieta E, Gómez-Beneyto M: 
Persistent cognitive dysfunctions in bipolar I disorder and 
schizophrenic patients: a three-year follow-up study.  Psychother 
Psychosom 2005, 74:113-119.
27. American Psychiatric Association: Diagnostic and Statistical Manual of 
Mental Disorders. DSM-IV.  Washington DC 4th edition. 1994.
28. Wing JK, Babor T, Brugha T, Cooper JE, Giel R, Jablenski A, Regier D, 
Sartorius N: SCAN. Schedules for Clinical Assessment in 
Neuropsychiatry.  Arch Gen Psychiatry 1990, 47:589-593.
29. Marangell LB, Yudofsky SC, Silver JM: Antipsychotic drugs.  In Textbook of 
Psychiatry 3rd edition. Edited by: Hales, RE, Yudofsky SC, Talbott JA. 
Wahington DC: American Psychiatric Press; 1999:1064. 
30. Woods SW: Chlorpromazine equivalent doses for the newer atypical 
antipsychotics.  J Clin Psychiatry 2003, 64:663-667.
31. Kay SR, Fiszbein A, Vital-Herne M, Fuentes LS: The Positive and Negative 
Syndrome Scale-Spanish adaptation.  J Nerv Ment Dis 1990, 178:510-517.
32. Peralta-Martín V, Cuesta-Zorita MJ: Validation of positive and negative 
symptom scale (PANSS) in a sample of Spanish schizophrenic patients.  
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1994, 22:171-177.
33. Hamilton M: A rating scale for depression.  J Neurol Neurosurg Psychiatry 
1960, 23:56-62.
34. Ramos-Brieva JA, Cordero-Villafáfila A: New validation of the Hamilton 
Rating Scale for Depression.  J Psychiatr Res 1998, 22:21-28.
35. Phillips L: Case history data and prognosis in schizophrenia.  J Nerv Ment 
Dis 1953, 117:515-525.
36. Tabarés-Seisdedos R, Sanjuan-Arias J, Gómez-Beneyto M, Leal-Cercos C: 
Early age of onset, brain morphological changes and non-consistent 
motor asymmetry in schizophrenic patients.  Schizophr Res 1999, 
37:25-31.
37. Selva G, Salazar J, Balanzá-Martínez V, Rubio C, Daban C, Sánchez-Moreno 
J, Vieta E, Tabarés-Seisdedos R: Bipolar I patients with and without a 
history of psychotic symptoms: do they differ in their cognitive 
functioning?  J Psychiatr Res 2007, 41:265-272.
38. Ardila A, Rosselli M, Puente A: Neuropsychological Evaluation of the 
Spanish Speaker.  Plenum Press, New York; 1994. 
39. Woodward ND, Purdon SE, Meltzer HY, Zaldh DH: A meta-analysis of 
cognitive change with haloperidol in clinical trials of atypical 
antipsychotics: dose effects and comparison to practice effects.  
Schizophr Res 2007, 89:211-224.
40. Wittorf A, Sickinger S, G Klingberg S: Neurocognitive effects of atypical 
and conventional antipsychotic drugs in schizophrenia: a naturalistic 
six-month follow-up study.  Arch Clin Neuropsychol 2008, 23:271-282.
41. Kawai N, Yamakawa Y, Baba A, Nemoto K, Tachikawa H, Hori T, Asada T, 
Iidaka T: High-dose of multiple antipsychotics and cognitive function in 
schizophrenia: the effect of dose-reduction.  Prog 
Neuropsychopharmacol Biol Psychiatry 2006, 30:1009-1014.
42. Saeedi H, Remington G, Christensen BK: Impact of haloperidol, a 
dopamine D2 antagonist, on cognition and mood.  Schizophr Res 2006, 
85:222-231.
43. Keefe RS, Seidman LJ, Christensen BK, Harmer RF, Sharma T, Sistskoorn 
MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger 
TM, Lieberman JA: Comparative effect of atypical and conventional 
antipsychotic drugs on neurocognition in first-episode psychosis: a 
randomized, double-blind trial of olanzapine versus low doses of 
haloperidol.  Am J Psychiatry 2004, 161:985-995.
44. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and 
olanzapine on cognitive function in schizophrenia.  Schizophr Bull 1999, 
25:233-235.
45. Newton S, Duman R: Neurogenic actions of atypical antipsychotic 
drugs and therapeutic implications.  CNS Drugs 2007, 21:715-725.
46. Frey BN Gomes FA, Tramontina J, Kauer-Sant'anna M, Grassi-Oliveira R, 
Post RM: Allostatic load in bipolar disorder: implications for 
pathophysiology and treatment.  Neurosci Biobehav Rev 2008, 
32:675-692.
Selva-Vera et al. BMC Psychiatry 2010, 10:47
http://www.biomedcentral.com/1471-244X/10/47
Page 10 of 10Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-244X/10/47/prepub
doi: 10.1186/1471-244X-10-47
Cite this article as: Selva-Vera et al., The switch from conventional to atypical 
antipsychotic treatment should not be based exclusively on the presence of 
cognitive deficits. A pilot study in individuals with schizophrenia BMC Psychi-
atry 2010, 10:47
